<div id="readability-page-1"><div> By Jason Chau <pre></pre> Shares of Daiichi Sankyo tumbled after the Japanese drugmaker delayed the release of its earnings results. Daiichi Sankyo's stock declined nearly 11% to 2,497.50 yen, equivalent to $15.64, in Friday morning's trading session in Tokyo, marking its steepest intraday decline since August 2024. The pharmaceutical company said it will report the results for the fiscal year ended March 2026 on May 11, instead of the originally scheduled April 27. It attributed the delay to a review of its supply plans for its oncology portfolio and development pipeline, and further deliberations to estimate the loss provisions related to contract manufacturing. Daiichi Sankyo said it would also release its five-year business plan for 2026-2030 on May 11, brought forward from May 19. The delay in the earnings release comes amid rapid changes in the drugmaker's business environment as it pivots toward innovative drug discovery, particularly in the field of oncology. Earlier this month, it agreed to sell its over-the-counter drug business to Japanese beverage giant Suntory Holdings for about $1.55 billion. Daiichi Sankyo shares are down nearly 26% so far this year. <pre></pre> Write to Jason Chau at jason.chau@wsj.com <pre></pre> (END) Dow Jones Newswires April 24, 2026 01:03 ET (05:03 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

4568

第一三共株式会社(ADR)

第一三共株式会社 (ADR) 的股价下跌近 11%，至 2,497.50 日元，此前该公司因审查其肿瘤学产品组合和合同制造条款，将截至 2026 年 3 月的财报发布推迟至 5 月 11 日。该公司还计划在同一天发布其 2026-2030 年的五年商业计划。此次推迟发生在第一三共转向创新药物研发之际，该公司最近以 15.5 亿美元将其非处方药业务出售给了三得利控股。今年该股价已下跌近 26%

Shares of Japanese Drugmaker Daiichi Sankyo Tumble on Delay in Earnings

日本制药公司第一三共株式会社 (ADR) 的股价因推迟公布收益而下跌